re-evaluated based on safety reports submitted by the marketing authorisation holders and in the case of new relevant information becoming available. Regarding the prescribing information for these products, CHMP has recommended new warnings for rosiglitazone products, specifically that, in patients with ischaemic heart disease, rosiglitazone should only be used after careful evaluation of each patientâ€™s individual risk. In contrast, no changes to the product information of pioglitazone were considered necessary in October 2007.